Court Rules Against FTC in Illumina Antitrust Case

A US judge has ruled against the Federal Trade Commission (FTC) in its antitrust case against Illumina. The agency had sued the company for its $7 Billion buyout of Grail, a biotech that tests for cancer using blood samples. Illumina is a leader in DNA sequencers used by Grail and its competitors, which the FTC claimed would make the deal anti-competitive.

According to Jared Whitlock, “In response to the FTC’s lawsuit, Illumina has touted its growing competition in court filings in hopes of securing Grail, which is chasing a cancer testing market that could be worth as much as $50 billion by 2035.”

To read more, click here.

(Source: Endpoints News, September 1^st, 2022)